Allurion Technologies Files for IPO
Ticker: ALURW · Form: S-1 · Filed: Dec 10, 2024 · CIK: 1964979
Sentiment: neutral
Topics: ipo, sec-filing, medical-devices
TL;DR
Allurion Tech is going public, filing its S-1 today. Get ready.
AI Summary
Allurion Technologies, Inc. filed an S-1 form on December 10, 2024, indicating its intention to go public. The company, formerly known as Allurion Technologies Holdings, Inc. until February 7, 2023, is based in Natick, MA, and operates in the surgical and medical instruments sector. This filing marks a significant step towards its public market debut.
Why It Matters
This S-1 filing signals Allurion Technologies' move towards becoming a publicly traded company, which could impact its funding, growth, and the medical device market.
Risk Assessment
Risk Level: medium — As a company pursuing an IPO, Allurion faces inherent market risks and the uncertainties associated with public trading.
Key Players & Entities
- ALLURION TECHNOLOGIES, INC. (company) — Filer
- ALLURION TECHNOLOGIES HOLDINGS, INC. (company) — Former Company Name
- 11 HURON DR STE 200 (location) — Business and Mail Address
- NATICK, MA (location) — City, State
- 508-647-4000 (phone_number) — Business Phone
FAQ
What is the primary business of Allurion Technologies, Inc.?
Allurion Technologies, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its SIC code 3841.
When did the company change its name?
The company changed its name from Allurion Technologies Holdings, Inc. on February 7, 2023.
Where is Allurion Technologies, Inc. headquartered?
Allurion Technologies, Inc. is located at 11 Huron Dr Ste 200, Natick, MA 01760.
What is the filing date of this S-1 form?
This S-1 form was filed on December 10, 2024.
What is the SEC file number for this filing?
The SEC file number for this S-1 filing is 333-283701.
Filing Stats: 4,458 words · 18 min read · ~15 pages · Grade level 17.7 · Accepted 2024-12-10 06:13:12
Key Financial Figures
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
- $0.0001 — rice of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will
- $0.37 — ock on the NYSE on December 6, 2024 was $0.37. Our existing public warrants (the "Pub
- $0.035 — nts on the NYSE on December 6, 2024 was $0.035 per warrant. Our July 2024 Public Warra
- $1.20 — fined herein) have an exercise price of $1.20 per warrant. Neither the pre-funded war
Filing Documents
- d915839ds1.htm (S-1) — 5018KB
- d915839dex231.htm (EX-23.1) — 1KB
- d915839dexfilingfees.htm (EX-FILING FEES) — 30KB
- g915839g01a03.jpg (GRAPHIC) — 20KB
- g915839g81a01.jpg (GRAPHIC) — 118KB
- g915839g82a01.jpg (GRAPHIC) — 56KB
- g915839g83a01.jpg (GRAPHIC) — 129KB
- g915839g83a02.jpg (GRAPHIC) — 139KB
- g915839g86a01.jpg (GRAPHIC) — 75KB
- g915839g87a01.jpg (GRAPHIC) — 164KB
- 0001193125-24-273671.txt ( ) — 22020KB
- alur-20240930.xsd (EX-101.SCH) — 126KB
- alur-20240930_cal.xml (EX-101.CAL) — 81KB
- alur-20240930_def.xml (EX-101.DEF) — 649KB
- alur-20240930_lab.xml (EX-101.LAB) — 850KB
- alur-20240930_pre.xml (EX-101.PRE) — 812KB
- d915839ds1_htm.xml (XML) — 4094KB
USE OF PROCEEDS
USE OF PROCEEDS 76 MARKET PRICE AND DIVIDEND INFORMATION 78 CAPITALIZATION 79
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 110 MANAGEMENT 135
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 146 DIRECTOR COMPENSATION 151 PRINCIPAL STOCKHOLDERS 153 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 156
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 161
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 174 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 177 PLAN OF DISTRIBUTION 183 LEGAL MATTERS 186 EXPERTS 186 WHERE YOU CAN FIND MORE INFORMATION 186 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus, and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the placement agent have authorized anyone to provide you with information that is different from, or in addition to, that contained in this prospectus, any amendment or supplement to this prospectus and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the placement agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the securities offered hereby. Our business, financial condition, results of operations and prospects may have changed since that date. Neither we nor the placement agent have taken any action that would permit this offering, or possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus applicable to that jurisdiction. This prospectus contains summarie
Forward-looking statements in this prospectus include, but are not limited to, statements about our ability to
Forward-looking statements in this prospectus include, but are not limited to, statements about our ability to: realize the benefits expected from the business combination (the "Business Combination") between Allurion and Compute Health Acquisition Corp. ("Compute Health") pursuant to that certain Business Combination Agreement, dated as of February 9, 2023 (as amended, the "Business Combination Agreement"), by and among Allurion, Legacy Allurion, Compute Health, Compute Health Corp., ("Merger Sub I") and Compute Health LLC ("Merger Sub II" and, together with Merger Sub I, the "Merger Subs"); successfully defend litigation that may be instituted by or against us; manage various conflicts of interest that could arise among us or our affiliates, investors, directors, and officers; successfully manage our cash and cash equivalents and any anticipated proceeds from this offering or the Chardan Equity Facility (as defined herein); maintain the listing of our securities on the NYSE, and the potential liquidity and trading of such securities; achieve the benefits of the collaboration with Medtronic plc ("Medtronic"); acquire sufficient sources of funding if and when needed; attract and retain key employees, officers, and directors; implement and achieve business plans, forecasts, and other expectations, including any financial projections provided to PIPE Investors (as defined herein) in connection with the Business Combination, the Purchasers in connection with the Notes (each as defined herein), and the investors in any offering hereunder, and identify and realize additional opportunities; manage risks associated with our management having limited experience operating as a public company; commercialize current and future products and services and create sufficient demand among health care providers and patients for such products, including the recent launch of our compounded GLP-1 program and achieving the expected benefits of such program; succes